A citation-based method for searching scientific literature

Pierre Delanaye, Karl Martin Wissing, Andre J Scheen. Clin Kidney J 2021
Times Cited: 3







List of co-cited articles
32 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation.
Hiddo J L Heerspink, David Z I Cherney. Clin J Am Soc Nephrol 2021
11
66

Preventing and treating kidney disease in patients with type 2 diabetes.
Pierre Delanaye, André J Scheen. Expert Opin Pharmacother 2019
18
66

Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin, Michael W Fong,[...]. Diabetes Obes Metab 2021
7
66

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
767
66

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
294
66


Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes.
Carissa Vinovskis, Lu-Ping Li, Pottumarthi Prasad, Kalie Tommerdahl, Laura Pyle, Robert G Nelson, Meda E Pavkov, Daniel van Raalte, Marian Rewers, Marlon Pragnell,[...]. Diabetes 2020
11
66

Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis.
Dario Giugliano, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito. Diabetes Obes Metab 2021
10
66


Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus.
Charuhas V Thakar, Annette Christianson, Jonathan Himmelfarb, Anthony C Leonard. Clin J Am Soc Nephrol 2011
291
66

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Avivit Cahn, Cheli Melzer-Cohen, Rena Pollack, Gabriel Chodick, Varda Shalev. Diabetes Obes Metab 2019
42
66


Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
David Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, Francesco Cosentino, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Jie Liu, Shuai Wang,[...]. Clin Cardiol 2021
7
66

The hyperfiltration theory: a paradigm shift in nephrology.
B M Brenner, E V Lawler, H S Mackenzie. Kidney Int 1996
564
66

Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron.
Anita T Layton, Volker Vallon, Aurélie Edwards. Am J Physiol Renal Physiol 2016
76
66

Cardiorenal Syndrome Revisited.
Faiez Zannad, Patrick Rossignol. Circulation 2018
102
66


Biomarkers and physiopathology in the cardiorenal syndrome.
Antoine Bouquegneau, Jean-Marie Krzesinski, Pierre Delanaye, Etienne Cavalier. Clin Chim Acta 2015
19
66

Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
A Perlman, S N Heyman, I Matok, J Stokar, M Muszkat, A Szalat. Nutr Metab Cardiovasc Dis 2017
48
66

The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
Anne C Hesp, Jennifer A Schaub, Pottumarthi V Prasad, Volker Vallon, Gozewijn D Laverman, Petter Bjornstad, Daniël H van Raalte. Kidney Int 2020
39
66

An update on the safety of SGLT2 inhibitors.
André J Scheen. Expert Opin Drug Saf 2019
63
66

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Girish N Nadkarni, Rocco Ferrandino, Alexander Chang, Aditya Surapaneni, Kinsuk Chauhan, Priti Poojary, Aparna Saha, Bart Ferket, Morgan E Grams, Steven G Coca. Diabetes Care 2017
88
66

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Gert J Mayer, Christoph Wanner, Matthew R Weir, Silvio E Inzucchi, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z I Cherney. Kidney Int 2019
54
66

We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury.
Vikas S Sridhar, Katherine R Tuttle, David Z I Cherney. Am J Kidney Dis 2020
11
66

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
66

Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.
Carina Iskander, David Z Cherney, Kristin K Clemens, Stephanie N Dixon, Ziv Harel, Nivethika Jeyakumar, Eric McArthur, Flory Tsobo Muanda, Chirag R Parikh, J Michael Paterson,[...]. CMAJ 2020
22
66

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Erik J van Bommel, Hiddo J L Heerspink, Daniël H van Raalte, Jaap A Joles. J Am Soc Nephrol 2017
269
66

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
66



The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Erik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, Lennart Tonneijck, Mark M Smits, Anna L Emanuel, Andrea Bozovic, A H Jan Danser, Frank Geurts, Ewout J Hoorn,[...]. Kidney Int 2020
116
66

Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial.
Jens Christian Laursen, Niels Søndergaard-Heinrich, Joana Mendes Lopes de Melo, Bryan Haddock, Ida Kirstine Bull Rasmussen, Farzaneh Safavimanesh, Christian Stevns Hansen, Joachim Størling, Henrik Bo Wiberg Larsson, Per-Henrik Groop,[...]. EClinicalMedicine 2021
7
66

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
JingWei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L Neuen, Clare Arnott, Roger Simpson, Richard Oh, Kenneth W Mahaffey, Hiddo J L Heerspink. Kidney Int 2020
23
33

Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Vincent L M Esnault, Amr Ekhlas, Catherine Delcroix, Marie-Geneviève Moutel, Jean-Michel Nguyen. J Am Soc Nephrol 2005
80
33

Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
Pierpaolo Pellicori, David Fitchett, Mikhail N Kosiborod, Anne P Ofstad, Leo Seman, Bernard Zinman, Isabella Zwiener, Christoph Wanner, Jyothis George, Silvio E Inzucchi,[...]. Eur J Heart Fail 2021
9
33

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Glenn M Chertow, Priya Vart, Niels Jongs, Robert D Toto, Jose Luis Gorriz, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström,[...]. J Am Soc Nephrol 2021
15
33

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.
Nikolaus Marx, Melanie J Davies, Peter J Grant, Chantal Mathieu, John R Petrie, Francesco Cosentino, John B Buse. Lancet Diabetes Endocrinol 2021
33
33

Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function.
Saijun Zhou, YuLing Zhang, TongDan Wang, Shuai Huang, Siyi Gong, Junmei Wang, Pei Yu. Diabetes Metab 2021
2
50

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
143
33

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.
Lesley A Inker, Hasi Mondal, Tom Greene, Taylor Masaschi, Francesco Locatelli, Francesco P Schena, Ritsuko Katafuchi, Gerald B Appel, Bart D Maes, Philip K Li,[...]. Am J Kidney Dis 2016
57
33

SGLT2 inhibitors: β blockers for the kidney?
Richard E Gilbert. Lancet Diabetes Endocrinol 2016
28
33

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel,[...]. Eur Heart J 2021
566
33

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Mariam Elmegaard Malik, Emil Loldrup Fosbøl,[...]. Lancet Diabetes Endocrinol 2021
32
33

The tubular hypothesis of nephron filtration and diabetic kidney disease.
Volker Vallon, Scott C Thomson. Nat Rev Nephrol 2020
86
33

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Meg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, Carinna Hockham, Qiang Li, Rajiv Agarwal, George L Bakris, Christopher P Cannon, David M Charytan, Tom Greene,[...]. Clin J Am Soc Nephrol 2021
11
33



Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
T H Jafar, C H Schmid, M Landa, I Giatras, R Toto, G Remuzzi, G Maschio, B M Brenner, A Kamper, P Zucchelli,[...]. Ann Intern Med 2001
738
33



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.